DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $30,239,000 | -3.5% | 112,705 | -19.1% | 1.29% | +17.9% |
| Q1 2021 | $31,340,000 | -13.1% | 139,238 | -14.3% | 1.10% | +0.5% |
| Q4 2020 | $36,077,000 | -13.5% | 162,458 | -16.2% | 1.09% | +8.0% |
| Q3 2020 | $41,716,000 | +294.9% | 193,822 | +224.1% | 1.01% | +161.9% |
| Q2 2020 | $10,565,000 | +23.1% | 59,800 | -3.5% | 0.39% | +4.9% |
| Q1 2020 | $8,580,000 | -13.1% | 62,000 | -3.6% | 0.37% | +10.8% |
| Q4 2019 | $9,869,000 | +6.3% | 64,300 | 0.0% | 0.33% | -3.5% |
| Q3 2019 | $9,282,000 | -1.6% | 64,300 | -2.6% | 0.34% | -1.4% |
| Q2 2019 | $9,430,000 | +8.3% | 66,000 | 0.0% | 0.35% | +3.3% |
| Q1 2019 | $8,711,000 | +28.0% | 66,000 | 0.0% | 0.34% | +19.9% |
| Q4 2018 | $6,804,000 | -18.7% | 66,000 | -14.3% | 0.28% | +10.2% |
| Q3 2018 | $8,365,000 | +10.1% | 77,000 | 0.0% | 0.26% | +4.5% |
| Q2 2018 | $7,598,000 | +7.8% | 77,000 | +6.9% | 0.24% | -4.3% |
| Q1 2018 | $7,047,000 | +5.4% | 72,000 | 0.0% | 0.26% | +8.0% |
| Q4 2017 | $6,684,000 | +8.2% | 72,000 | 0.0% | 0.24% | +8.2% |
| Q3 2017 | $6,175,000 | +1.6% | 72,000 | 0.0% | 0.22% | -1.8% |
| Q2 2017 | $6,076,000 | -1.3% | 72,000 | 0.0% | 0.22% | -4.3% |
| Q1 2017 | $6,158,000 | +9.8% | 72,000 | 0.0% | 0.23% | +10.4% |
| Q4 2016 | $5,608,000 | -0.6% | 72,000 | 0.0% | 0.21% | -3.2% |
| Q3 2016 | $5,643,000 | -22.4% | 72,000 | 0.0% | 0.22% | -24.8% |
| Q2 2016 | $7,271,000 | -29.0% | 72,000 | -33.3% | 0.29% | -29.8% |
| Q1 2016 | $10,247,000 | +67.2% | 108,000 | +63.6% | 0.41% | +64.5% |
| Q4 2015 | $6,128,000 | +79.9% | 66,000 | +65.0% | 0.25% | +64.1% |
| Q3 2015 | $3,407,000 | -49.6% | 40,000 | -49.4% | 0.15% | -39.8% |
| Q2 2015 | $6,758,000 | -7.4% | 79,000 | -8.1% | 0.25% | +9.5% |
| Q1 2015 | $7,300,000 | -8.4% | 86,000 | -7.5% | 0.23% | +14.3% |
| Q4 2014 | $7,970,000 | +34.5% | 93,000 | +19.2% | 0.20% | +18.7% |
| Q3 2014 | $5,927,000 | +23.5% | 78,000 | +27.9% | 0.17% | +12.5% |
| Q2 2014 | $4,801,000 | +5.0% | 61,000 | 0.0% | 0.15% | 0.0% |
| Q1 2014 | $4,574,000 | -2.9% | 61,000 | 0.0% | 0.15% | -11.6% |
| Q4 2013 | $4,709,000 | – | 61,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |